MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

GlycoMimetics Inc

Closed

SectorHealthcare

0.24 4.35

Overview

Share price change

24h

Current

Min

0.22

Max

0.25

Key metrics

By Trading Economics

Income

2.6M

-7.2M

EPS

-0.112

Employees

4

EBITDA

399K

-5.3M

Dividends

By Dow Jones

Next Earnings

8 May 2025

Market Stats

By TradingEconomics

Market Cap

14M

Previous open

-4.11

Previous close

0.24

Technical Score

By Trading Central

Confidence

Bullish Evidence

GlycoMimetics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

25 Jul 2024, 15:11 UTC

Major Market Movers

GlycoMimetics Shares Drop 27% After Restructuring Plan, Job Cuts

Peer Comparison

Price change

GlycoMimetics Inc Forecast

Rating Consensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

0.223 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About GlycoMimetics Inc

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.